Verax Biomedical, Incorporated specializes in advanced technologies for ensuring the safety of blood transfusions, particularly through its Platelet PGD Test. This rapid test is designed to detect bacterial contamination in platelets, providing a critical safety measure for transfusion medicine. It is the only FDA-cleared test that can be performed within 24 hours prior to transfusion, significantly enhancing patient safety by identifying contaminated units that may have been missed by traditional culture-based methods. The Platelet PGD Test boasts a remarkable specificity of 99.9% and can deliver results in approximately 30 minutes, making it both efficient and user-friendly. This technology is particularly vital as it allows for the safe dating of platelets up to seven days, addressing FDA guidance on bacterial risks in transfusions.

The underlying technology of Verax's testing system is based on its patented Pan Genera Detection (PGD) technology, which leverages the detection of conserved antigens found in both Gram-positive and Gram-negative bacteria. By targeting these shared antigens, the PGD technology enables the identification of a broad spectrum of bacterial contaminants without relying on indirect measures of bacterial presence. This innovative approach not only enhances the sensitivity and specificity of bacterial detection in blood components but also has potential applications beyond transfusion medicine, including patient diagnostics, food safety, and environmental testing. Verax Biomedical's commitment to improving blood safety through rapid and effective testing solutions positions it as a leader in the field of transfusion medicine.

United States

Verax Biomedical is a biomedical technology company that specializes in platelet bacterial contamination detection in cells and tissues intended for transfusion and transplantation.

Verax Biomedical, Incorporated

Company Details